RxDoctor Payments Data

Lauren Lane, DO

Internal Medicine · Grand Haven, MINPI 1225299928

Payments from drug & device makers

$1,560in general payments, 2019–2025

Across 90 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$468
  • Pfizer$338
  • AstraZeneca$261
  • AbbVie$232
  • GSK$106
  • Novartis$59
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$1,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,560 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$47,120
Medicare patients
133
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$62,938
OzempicSemaglutide40$58,935
TrulicityDulaglutide44$52,862
MounjaroTirzepatide23$35,179
JanuviaSitagliptin Phosphate33$30,984
JardianceEmpagliflozin17$25,728
FarxigaDapagliflozin Propanediol26$22,540
XareltoRivaroxaban14$14,452
Rosuvastatin Calcium488$10,066
Tresiba Flextouch U-100Insulin Degludec16$9,453
Levothyroxine Sodium457$9,441
Atorvastatin Calcium550$9,049
Breo ElliptaFluticasone/Vilanterol14$5,297
Losartan Potassium249$4,760
Omeprazole233$4,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$28$88,04167 claims
PfizerEliquis$338$62,93849 claims
Novo NordiskOzempic$468$58,93540 claims
AstraZenecaFarxiga$261$22,54026 claims
GSKBreo Ellipta$106$5,29714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Haven

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →